Journal Home > Volume 3 , Issue 1
Journal of Neurorestoratology 2015, 3(1): 109-114 https://doi.org/10.2147/JN.S74145
Review | Open Access | Issue | Published: 06 August 2015

Clinical neurorestorative progress in amyotrophic lateral sclerosis

Show Author's Information Lin Chen1,2,5( ),  Hongyun Huang3( ),  Haitao Xi4,5,  Gengsheng Mao3
Medical Center, Tsinghua University,
Tsinghua University Yuquan Hospital,
General Hospital of Chinese People’s Armed Police Forces,
Beijing Rehabilitation Hospital of Capital Medical University,
Beijing Hongtianji Neuroscience Academy, Beijing, People’s Republic of China
Keywords:
cell transplantation, amyotrophic lateral sclerosis, neurorestorative treatment, clinical trial
Cite this article:
Chen L, Huang H, Xi H, et al. Clinical neurorestorative progress in amyotrophic lateral sclerosis. Journal of Neurorestoratology, 2015, 3(1): 109-114. https://doi.org/10.2147/JN.S74145
Download citation
EndNote(RIS)
BibTeX

390

Views

19

Downloads

Citations

2

Crossref

5

WoS

0

Scopus

N/A

CSCD

Abstract Full text About this article

Amyotrophic lateral sclerosis is a progressive and fatal neurodegenerative disease characterized by progressive paralysis and motor neuron death. In addition to symptomatic managements such as ventilation and nutritional support, neurorestorative therapies have demonstrated anti-neurodegenerative potential and may improve quality of life for patients. Currently, clinical neurorestorative strategies include pharmacological management (granulocyte colony stimulating factor), neuromodulatory intervention (repetitive transcranial magnetic and cortical stimulation), cell transplantation (bone marrow stromal cells, olfactory ensheathing cells, granulocyte colony stimulating factor-mobilized peripheral blood stromal cells, hematopoietic stem and progenitor cells, neural stem/progenitor cells, CD133+ cells and CD34+ cells), bioengineering and tissue engineering therapy, and combined neurorehabilitative treatment. In this review, we describe the latest progress in clinical neurorestorative management of amyotrophic lateral sclerosis and discuss the underlying evidence base.


menu
Abstract
Full text
Outline
About this article

Clinical neurorestorative progress in amyotrophic lateral sclerosis

Show Author's information Lin Chen1,2,5( ), Hongyun Huang3( ), Haitao Xi4,5, Gengsheng Mao3
Medical Center, Tsinghua University,
Tsinghua University Yuquan Hospital,
General Hospital of Chinese People’s Armed Police Forces,
Beijing Rehabilitation Hospital of Capital Medical University,
Beijing Hongtianji Neuroscience Academy, Beijing, People’s Republic of China

Abstract

Amyotrophic lateral sclerosis is a progressive and fatal neurodegenerative disease characterized by progressive paralysis and motor neuron death. In addition to symptomatic managements such as ventilation and nutritional support, neurorestorative therapies have demonstrated anti-neurodegenerative potential and may improve quality of life for patients. Currently, clinical neurorestorative strategies include pharmacological management (granulocyte colony stimulating factor), neuromodulatory intervention (repetitive transcranial magnetic and cortical stimulation), cell transplantation (bone marrow stromal cells, olfactory ensheathing cells, granulocyte colony stimulating factor-mobilized peripheral blood stromal cells, hematopoietic stem and progenitor cells, neural stem/progenitor cells, CD133+ cells and CD34+ cells), bioengineering and tissue engineering therapy, and combined neurorehabilitative treatment. In this review, we describe the latest progress in clinical neurorestorative management of amyotrophic lateral sclerosis and discuss the underlying evidence base.

Keywords: cell transplantation, amyotrophic lateral sclerosis, neurorestorative treatment, clinical trial

References(63)

1.
Sejvar JJ, Holman RC, Bresee JS, Kochanek KD, Schonberger LB. Amyotrophic lateral sclerosis mortality in the United States, 1979–2001. Neuroepidemiology. 2005;25:144–152.
DOI Google Scholar
2.
Worms PM. The epidemiology of motor neuron diseases: a review of recent studies. J Neurol Sci. 2001;191:3–9.
DOI Google Scholar
3.
Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995;118:707–719.
DOI Google Scholar
4.
Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59–62.
DOI Google Scholar
5.
Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol. 1995;38:73–84.
DOI Google Scholar
6.
Ferrante RJ, Browne SE, Shinobu LA, et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem. 1997;69:2064–2074.
DOI Google Scholar
7.
Smith RG, Henry YK, Mattson MP, Appel SH. Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol. 1998;44:696–699.
DOI Google Scholar
8.
Ro LS, Lai SL, Chen CM, Chen ST. Deleted 4977-bp mitochondrial DNA mutation is associated with sporadic amyotrophic lateral sclerosis: a hospital-based case-control study. Muscle Nerve. 2003;28:737–743.
DOI Google Scholar
9.
Reid E, Kloos M, Ashley-Koch A, et al. A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am J Hum Genet. 2002;71:1189–1194.
DOI Google Scholar
10.
Hirano A, Donnenfeld H, Sasaki S, Nakano I. Fine structural observations of neurofilamentous changes in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 1984;43:461–470.
DOI Google Scholar
11.
Hirano A, Nakano I, Kurland LT, Mulder DW, Holley PW, Saccomanno G. Fine structural study of neurofibrillary changes in a family with amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 1984;43:471–480.
DOI Google Scholar
12.
Carpenter S. Proximal axonal enlargement in motor neuron disease. Neurology. 1968;18:841–851.
DOI Google Scholar
13.
Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1218–1226.
DOI Google Scholar
14.
Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1227–1233.
DOI Google Scholar
15.
Zoccolella S, Santamato A, Lamberti P. Current and emerging treatments for amyotrophic lateral sclerosis. Neuropsychiatr Dis Treat. 2009;5:577–595.
DOI Google Scholar
16.
Boll MC, Bayliss L, Vargas-Cañas S, et al. Clinical and biological changes under treatment with lithium carbonate and valproic acid in sporadic amyotrophic lateral sclerosis. J Neurol Sci. 2014;340:103–108.
DOI Google Scholar
17.
Verstraete E, Veldink JH, Huisman MH, et al. Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial. J Neurol Neurosurg Psychiatry. 2012;83:557–564.
DOI Google Scholar
18.
Gianforcaro A, Hamadeh MJ. Vitamin D as a potential therapy in amyotrophic lateral sclerosis. CNS Neurosci Ther. 2014;20:101–111.
DOI Google Scholar
19.
Grassinger J, Khomenko A, Hart C, et al. Safety and feasibility of long term administration of recombinant human granulocyte-colony stimulating factor in patients with amyotrophic lateral sclerosis. Cytokine. 2014;67:21–28.
DOI Google Scholar
20.
Di Lazzaro V, Dileone M, Pilato F, et al. Repetitive transcranial magnetic stimulation for ALS. A preliminary controlled study. Neurosci Lett. 2006;408:135–140.
DOI Google Scholar
21.
Di Lazzaro V, Pilato F, Profice P, et al. Motor cortex stimulation for ALS: a double blind placebo-controlled study. Neurosci Lett. 2009;464:18–21.
DOI Google Scholar
22.
Zanette G, Forgione A, Manganotti P, Fiaschi A, Tamburin S. The effect of repetitive transcranial magnetic stimulation on motor performance, fatigue and quality of life in amyotrophic lateral sclerosis. J Neurol Sci. 2008;270:18–22.
DOI Google Scholar
23.
Sidoti C, Agrillo U. Chronic cortical stimulation for amyotrophic lateral sclerosis: a report of four consecutive operated cases after a 2-year follow-up: technical case report. Neurosurgery. 2006;58:E384.
DOI Google Scholar
24.
Orient-Lopez F, Terre-Boliart R, Guevara-Espinosa D, Bernabeu-Guitart M. Neurorehabilitation treatment of amyotrophic lateral sclerosis. Rev Neurol. 2006;43:549–555.
DOI Google Scholar
25.
Lewis M, Rushanan S. The role of physical therapy and occupational therapy in the treatment of amyotrophic lateral sclerosis. NeuroRehabilitation. 2007;22:451–461.
DOI Google Scholar
26.
Kühnlein P, Gdynia HJ, Sperfeld AD, et al. Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis. Nat Clin Pract Neurol. 2008;4:366–374.
DOI Google Scholar
27.
Sanjak M, Bravver E, Bockenek WL, Norton HJ, Brooks BR. Supported treadmill ambulation for amyotrophic lateral sclerosis: a pilot study. Arch Phys Med Rehabil. 2010;91:1920–1929.
DOI Google Scholar
28.
Arbesman M, Sheard K. Systematic review of the effectiveness of occupational therapy-related interventions for people with amyotrophic lateral sclerosis. Am J Occup Ther. 2014;68:20–26.
DOI Google Scholar
29.
Cordes AL, Jahn K, Hass R, et al. Intramedullary spinal cord implantation of human CD34(+) umbilical cord-derived cells in ALS. Amyotroph Lateral Scler. 2011;12:325–330.
DOI Google Scholar
30.
Lunn JS, Hefferan MP, Marsala M, Feldman EL. Stem cells: comprehensive treatments for amyotrophic lateral sclerosis in conjunction with growth factor delivery. Growth Factors. 2009;27:133–140.
DOI Google Scholar
31.
Sun H, Bénardais K, Stanslowsky N, et al. Therapeutic potential of mesenchymal stromal cells and MSC conditioned medium in amyotrophic lateral sclerosis (ALS) – in vitro evidence from primary motor neuron cultures, NSC-34 cells, astrocytes and microglia. PLoS One. 2013;8:e72926.
DOI Google Scholar
32.
Connick P, Chandran S. Mesenchymal stromal cell transplantation modulates neuroinflammatory milieu in amyotrophic lateral sclerosis. Cytotherapy. 2014;16:1031–1032.
DOI Google Scholar
33.
Mazzini L, Fagioli F, Boccaletti R, et al. Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:158–161.
DOI Google Scholar
34.
Mazzini L, Mareschi K, Ferrero I, et al. Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis. Neurol Res. 2006;28:523–526.
DOI Google Scholar
35.
Mazzini L, Mareschi K, Ferrero I, et al. Stem cell treatment in amyotrophic lateral sclerosis. J Neurol Sci. 2008;265:78–83.
DOI Google Scholar
36.
Mazzini L, Ferrero I, Luparello V, et al. Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a Phase I clinical trial. Exp Neurol. 2010;223:229–237.
DOI Google Scholar
37.
Karussis D, Karageorgiou C, Vaknin–Dembinsky A, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010;67:1187–1194.
DOI Google Scholar
38.
Cho GW, Noh MY, Kim HY, Koh SH, Kim KS, Kim SH. Bone marrow-derived stromal cells from amyotrophic lateral sclerosis patients have diminished stem cell capacity. Stem Cells Dev. 2010;19:1035–1042.
DOI Google Scholar
39.
Bossolasco P, Cova L, Calzarossa C, et al. Metalloproteinase alterations in the bone marrow of ALS patients. J Mol Med (Berl). 2010;88:553–564.
DOI Google Scholar
40.
Martínez HR, Marioni SS, Escamilla Ocañas CE, Gonzalez Garza MT, Moreno-Cuevas JE. Amyotrophic lateral sclerosis in pregnancy: clinical outcome during the post-partum period after stem cell transplantation into the frontal motor cortex. Cytotherapy. 2014;16:402–405.
DOI Google Scholar
41.
Huang H, Chen L, Xi H, et al. [Olfactory ensheathing cells transplantation for central nervous system diseases in 1255 patients]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2009;23:14–20. Chinese.
Google Scholar
42.
Chen L, Huang H, Xi H, et al. Intracranial transplant of olfactory ensheathing cells in children and adolescents with cerebral palsy: a randomized controlled clinical trial. Cell Transplant. 2010;19:185–191.
DOI Google Scholar
43.
Chen L, Huang H, Zhang J, et al. [Short–term outcome of olfactory ensheathing cells transplantation for treatment of amyotrophic lateral sclerosis]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2007;21:961–966. Chinese.
Google Scholar
44.
Huang H, Tan K, Chen L, et al. [MR spectroscopy evaluation and short–term outcome of olfactory ensheathing cells transplantation in amyotrophic lateral sclerosis patients]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2007;21:52–57. Chinese.
Google Scholar
45.
Huang H, Chen L, Xi H, et al. Fetal olfactory ensheathing cells transplantation in amyotrophic lateral sclerosis patients: a controlled pilot study. Clin Transplant. 2008;22:710–718.
DOI Google Scholar
46.
Chen L, Chen D, Xi H, et al. Olfactory ensheathing cell neurorestorotherapy for amyotrophic lateral sclerosis patients: benefits from multiple transplantations. Cell Transplant. 2012;21 Suppl 1:S65–S77.
DOI Google Scholar
47.
Cashman N, Tan LY, Krieger C, et al. Pilot study of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem cells in amyotrophic lateral sclerosis (ALS). Muscle Nerve. 2008;37:620–625.
DOI Google Scholar
48.
Appel SH, Engelhardt JI, Henkel JS, et al. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology. 2008;71:1326–1334.
DOI Google Scholar
49.
Deda H, Inci MC, Kürekçi AE, et al. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up. Cytotherapy. 2009;11:18–25.
DOI Google Scholar
50.
Martinez HR, Gonzalez-Garza MT, Moreno-Cuevas JE, Caro E, Gutierrez-Jimenez E, Segura JJ. Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients. Cytotherapy. 2009;11:26–34.
DOI Google Scholar
51.
Riley J, Federici T, Polak M, et al. Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I safety trial, technical note, and lumbar safety outcomes. Neurosurgery. 2012;71:405–416.
DOI Google Scholar
52.
Riley J, Glass J, Feldman EL, et al. Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I trial, cervical microinjection, and final surgical safety outcomes. Neurosurgery. 2014;74:77–87.
DOI Google Scholar
53.
Feldman EL, Boulis NM, Hur J, et al. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol. 2014;75:363–373.
DOI Google Scholar
54.
Aebischer P, Pochon NA, Heyd B, et al. Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF. Hum Gene Ther. 1996;7:851–860.
DOI Google Scholar
55.
Aebischer P, Schluep M, Deglon N, et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med. 1996;2:696–699.
DOI Google Scholar
56.
Zurn AD, Henry H, Schluep M, et al. Evaluation of an intrathecal immune response in amyotrophic lateral sclerosis patients implanted with encapsulated genetically engineered xenogeneic cells. Cell Transplant. 2000;9:471–484.
DOI Google Scholar
57.
Ramón-Cueto A, Avila J. Olfactory ensheathing glia: properties and function. Brain Res Bull. 1998;46:175–187.
DOI Google Scholar
58.
Li Y, Bao J, Khatibi NH, et al. Olfactory ensheathing cell transplantation into spinal cord prolongs the survival of mutant SOD1 (G93A) ALS rats through neuroprotection and remyelination. Anat Rec (Hoboken). 2011;294:847–857.
DOI Google Scholar
59.
Li Y, Chen L, Zhao Y, et al. Intracranial transplant of olfactory ensheathing cells can protect both upper and lower motor neurons in amyotrophic lateral sclerosis. Cell Transplant. 2013;22 Suppl 1:S51–S65.
DOI Google Scholar
60.
Zhao CP, Zhang C, Zhou SN, et al. Human mesenchymal stromal cells ameliorate the phenotype of SOD1-G93A ALS mice. Cytotherapy. 2007;9:414–426.
DOI Google Scholar
61.
Vercelli A, Mereuta OM, Garbossa D, et al. Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2008;31:395–405.
DOI Google Scholar
62.
Dileone M, Profice P, Pilato F, et al. Repetitive transcranial magnetic stimulation for ALS. CNS Neurol Disord Drug Targets. 2010;9:331–334.
DOI Google Scholar
63.
Goyal NA, Mozaffar T. Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs. Expert Opin Investig Drugs. 2014;23:1–11.
DOI Google Scholar
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Published: 06 August 2015
Issue date: December 2015

Copyright

© 2015 The Author(s).

Acknowledgements

We thank Lu Zheng and Jiangfeng Guo for collecting the relevant data for preparing this manuscript.

Rights and permissions

© 2015 Chen et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Return